4-Hydroxy-thalidomide
This product is a hydroxylated derivative of thalidomide, featuring a hydroxyl group at the 4-position of the phthalimide ring. This modification introduces an additional reactive handle for conjugation or derivatization while retaining the immunomodulatory and E3 ligase-binding properties of thalidomide. It is especially used as a building block in the synthesis of PROTACs and other heterobifunctional molecules.
Key Features and Benefits
-
4-Hydroxy Substitution: Provides a reactive hydroxyl group for functionalization.
-
E3 Ligase Binding: Retains affinity for cereblon (CRBN), enabling targeted protein degradation strategies.
-
Versatile Intermediate: Useful in synthesizing PROTACs and drug conjugates.
-
Chemical Flexibility: Hydroxyl group supports esterification, etherification, or linker attachment.
-
High Purity: Produced to ≥95% purity for reproducible synthetic applications.
Applications
-
PROTAC Development: Serves as a CRBN-binding ligand for targeted protein degradation.
-
Drug Discovery: Enables design of thalidomide-derived conjugates and analogs.
-
Bioconjugation: Attaches to linkers or payloads via the hydroxyl group.
-
Medicinal Chemistry: Acts as a versatile scaffold for novel therapeutic agents.
Storage and Handling
-
Storage: Store at –20 °C in a sealed, light-protected container.
-
Handling: Use under dry, inert conditions; prepare fresh solutions as needed.
This product combines cereblon-binding activity with a reactive hydroxyl group, specifically making it a key intermediate for PROTAC synthesis and drug design.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
